サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：慢性腎臓病治療薬市場：薬物クラス別、投与経路別、患者タイプ別、流通チャネル別、地域別- 規模、シェア、展望、機会分析、2022年～2030年
市場調査レポート
商品コード
1149881

慢性腎臓病治療薬市場：薬物クラス別、投与経路別、患者タイプ別、流通チャネル別、地域別- 規模、シェア、展望、機会分析、2022年～2030年

Chronic Kidney Disease Drugs Market, by Drug Class, by Route of Administration, by Patient Type by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
出版日: | 発行: Coherent Market Insights | ページ情報: 英文 206 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
慢性腎臓病治療薬市場：薬物クラス別、投与経路別、患者タイプ別、流通チャネル別、地域別- 規模、シェア、展望、機会分析、2022年～2030年
出版日: 2022年10月13日
発行: Coherent Market Insights
ページ情報: 英文 206 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

慢性腎臓病とは、長い年月をかけて徐々に腎臓の機能が低下していく病気です。慢性腎臓病は、慢性腎臓病とも呼ばれます。腎臓病が悪化すると、血液中に老廃物が大量に蓄積されます。慢性腎臓病に関連するその他の問題としては、高血圧、赤血球数の低下、骨の脆弱化、栄養不良、神経障害などが挙げられます。

慢性腎臓病の主な原因としては、糖尿病、高血圧、慢性糸球体腎炎、慢性腎盂腎炎、抗炎症薬の慢性使用、自己免疫疾患、多嚢胞性腎、アルポート病、先天性奇形、急性腎臓病の遷延などがあげられます。

市場力学

市場の主要プレイヤーは、規制機関からの承認取得に注力しており、これが予測期間中の市場成長の原動力となると予想されます。例えば、2020年9月、腎臓および心血管疾患を有する人々の治療を改善するファーストインクラス医薬品の開発に注力するバイオ医薬品企業であるアーデリックス社は、透析中の慢性腎臓病（CKD）成人患者の血清リンの制御を目的とするテナパノールの新薬申請（NDA）が米国食品医薬品局（FDA）に受理されたと発表しています。

政府機関による啓発活動、慢性腎臓病の有病率の増加、製品の上市などの要因が、世界の慢性腎臓病治療薬の市場成長を促進しています。例えば、2021年に米国疾病対策予防センターが発表した記事によると、7人に1人以上、つまり米国の成人の15％、3700万人が慢性腎臓病を患っていると推定されています。同出典によると、慢性腎臓病は45～64歳（12％）、18～44歳よりも65歳以上（38％）に多く見られるとされています。

本調査の主な特徴

  • 本レポートでは、世界の慢性腎臓病治療薬市場を詳細に分析し、2021年を基準年とした予測期間（2022-2030年）の市場規模および年平均成長率（CAGR％）を示しています。
  • 異なるセグメントにわたる潜在的な収益機会を解明し、この市場の魅力的な投資提案マトリクスを説明します。
  • また、市場の促進要因、抑制要因、機会、新製品の上市または承認、市場動向、地域別の展望、主要企業が採用する競合戦略などに関する重要な考察も行っています。
  • 世界の慢性腎臓病治療薬市場における主要企業のプロファイルを、企業ハイライト、製品ポートフォリオ、主なハイライト、業績、戦略などのパラメータに基づいて紹介しています。
  • この調査の一部としてカバーされている主要企業は、Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharmaceuticals, Inc., AbbVie Inc., ProKidney Corp., Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche AG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., GlaxoSmithKline plc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG, Johnson & Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc., Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Teva Pharmaceutical Industries Ltd., YUHAN, Caladrius Biosciences, Inc., UnicoCell Biomed CO. LTD, Akebia Therapeutics, Inc., Allena Pharmaceuticals, and KBP Biosciences Co., Ltd.
  • このレポートからの洞察は、マーケティング担当者や企業の経営陣が、将来の製品の発売、タイプのアップグレード、市場の拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことを可能にするでしょう。
  • このレポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界のさまざまな利害関係者を対象としています。
  • 利害関係者は、世界の慢性腎臓病治療薬市場の分析に使用される様々な戦略マトリクスを通じて、意思決定を容易にすることができます。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 前提条件
  • 略語の説明

第2章 市場の展望

  • レポート内容
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場スナップショット：薬物クラス別
    • 市場スナップショット：投与経路別
    • 市場スナップショット：患者タイプ別
    • 市場スナップショット：流通チャネル別
    • 市場スナップショット：地域別
  • コヒーレントオポチュニティマップ（COM）

第3章 市場力学、規制、および動向の分析

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
  • 規制のシナリオ
  • 主なハイライト
  • 研究開発
  • 共同研究、M&Aシナリオ
  • 主な発展
  • 最近の製品承認と上市
  • PEST分析
  • パイプライン分析
  • 疫学

第4章 慢性腎臓病治療薬の世界市場-コロナウイルス（COVID-19）パンデミックの影響

  • COVID-19の市場に対する影響
  • 慢性腎臓病治療薬の世界市場への影響
  • 臨床試験への影響

第5章 慢性腎臓病治療薬の世界市場：薬物クラス別、2017年～2030年

  • ACE阻害剤
  • アンジオテンシン受容体拮抗薬（ARB）
  • Bブロッカー
  • カルシウム拮抗薬
  • ループ利尿薬
  • 赤血球生成促進剤（ESA）
  • リン酸塩結合剤
  • その他

第6章 慢性腎臓病治療薬の世界市場：投与経路別、2017年～2030年

  • 経口投与
  • 皮下投与
  • 静脈内投与

第7章 慢性腎臓病治療薬の世界市場：患者タイプ別、2017年～2030年

  • 人工透析
  • その他

第8章 慢性腎臓病治療薬の世界市場：流通チャネル別、2017年～2030年

  • 病院内薬局
  • 小売薬局
  • オンライン薬局

第9章 慢性腎臓病治療薬の世界市場：地域別、2017年～2030年

  • 北米
  • 米国
  • カナダ
  • ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
  • その他のラテンアメリカ地域
  • 欧州
  • 英国
  • ドイツ
  • イタリア
  • フランス
  • スペイン
  • ロシア
  • その他の欧州地域
  • アジア太平洋地域
  • 中国
  • インド
  • 日本
  • ASEAN
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
  • 中東地域
  • GCC
  • イスラエル
  • その他の中東地域
  • アフリカ
  • 北アフリカ
  • 中央アフリカ
  • 南アフリカ

第10章 競合情勢

  • ヒートマップ分析
  • 企業プロファイル
    • Sanofi
    • AstraZeneca plc.
    • Amgen, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • AbbVie Inc.
    • ProKidney Corp.
    • Pfizer, Inc.
    • Bayer AG
    • F. Hoffmann-La Roche AG
    • Kissei Pharmaceutical Co., Ltd.
    • Reata Pharmaceuticals, Inc.
    • GlaxoSmithKline plc.
    • Ardelyx, Inc.
    • Boehringer Ingelheim International GmbH
    • Novo Nordisk A/S
    • Novartis AG
    • Johnson & Johnson
    • Astellas Pharma Inc.
    • Takeda Pharmaceutical Company Limited
    • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    • Kibow Biotech, Inc.
    • FibroGen, Inc.
    • Cara Therapeutics
    • Pieris Pharmaceuticals, Inc.
    • Mitsubishi Chemical Group Corporation
    • Pharmacosmos A/S
    • OPKO Health, Inc.
    • Covis Pharma
    • Tricida, Inc.
    • Eli Lilly and Company
    • Biosidus S.A.
    • Teva Pharmaceutical Industries Ltd.
    • YUHAN
    • Caladrius Biosciences, Inc.
    • UnicoCell Biomed CO. LTD.
    • Akebia Therapeutics, Inc.
    • Caladrius Biosciences, Inc.
    • Allena Pharmaceuticals
    • KBP Biosciences Co., Ltd.

第11章 セクション

  • 参考文献
  • 調査手法
目次
Product Code: CMI1713

Chronic kidney disease is a condition which is characterized by gradual loss of kidney function over time. Chronic kidney disease is also known as chronic renal disease. The kidney disease gets worse, wastes can build to high levels in your blood; other problems associated to chronic kidney disease are high blood pressure, a low red blood cell count, weak bones, poor nutrition, and nerve damage.

The main causes of chronic kidney disease include diabetes, hypertension, chronic glomerulonephritis, chronic pyelonephritis, chronic use of anti-inflammatory medication, autoimmune diseases, polycystic kidney disease, Alport disease, congenital malformations, and prolonged acute renal disease.

Market Dynamics

Key players in market are focused on gaining approvals from regulatory bodies, which is expected to drive the market growth over the forecast period. For instance, in September 2020, Ardelyx, Inc., a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) of tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.

Factors such as awareness initiatives by government bodies, increasing prevalence of chronic kidney disease, and product launches are driving the global chronic kidney disease drugs market growth. For instance, according to an article published by Centers for Disease Control and Prevention in 2021, more than 1 in 7, that is 15% of the U.S. adults or 37 million people, are estimated to have chronic kidney disease. According to same source, chronic kidney disease is more common in people aged 65 years or older (38%) than in people aged 45-64 years (12%) or 18-44 years.

Key features of the study:

  • This report provides an in-depth analysis of the global chronic kidney disease drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global chronic kidney disease drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharmaceuticals, Inc., AbbVie Inc., ProKidney Corp., Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche AG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., GlaxoSmithKline plc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG, Johnson & Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc., Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Teva Pharmaceutical Industries Ltd., YUHAN, Caladrius Biosciences, Inc., UnicoCell Biomed CO. LTD, Akebia Therapeutics, Inc., Allena Pharmaceuticals, and KBP Biosciences Co., Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic kidney disease drugs market.

Detailed Segmentation:

  • Global Chronic Kidney Disease Drugs Market, By Drug Class:
    • ACE Inhibitors
    • Angiotensin Receptor Blockers (ARBs)
    • B-Blockers
    • Calcium Channel Blockers
    • Loop Diuretics
    • Erythropoiesis-Stimulating Agents (ESAs)
    • Phosphate Binders
    • Others
  • Global Chronic Kidney Disease Drugs Market, By Route of Administration:
    • Oral
    • Subcutaneous
    • Intravenous
  • Global Chronic Kidney Disease Drugs Market, By Patient Type:
    • Dialysis
    • Others
  • Global Chronic Kidney Disease Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Chronic Kidney Disease Drugs Market, By Region:
    • North America
      • By Country
    • U.S.
    • Canada
    • Latin America
      • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Region/Country
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Sanofi*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • AstraZeneca plc.
    • Amgen, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • AbbVie Inc.
    • ProKidney Corp.
    • Pfizer, Inc.
    • Bayer AG
    • Hoffmann-La Roche AG
    • Kissei Pharmaceutical Co., Ltd.
    • Reata Pharmaceuticals, Inc.
    • GlaxoSmithKline plc
    • Ardelyx, Inc.
    • Boehringer Ingelheim International GmbH
    • Novo Nordisk A/S
    • Novartis AG
    • Johnson & Johnson
    • Astellas Pharma Inc.
    • Takeda Pharmaceutical Company Limited
    • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    • Kibow Biotech, Inc.
    • FibroGen, Inc.
    • Cara Therapeutics
    • Pieris Pharmaceuticals, Inc.
    • Mitsubishi Chemical Group Corporation
    • Pharmacosmos A/S
    • OPKO Health, Inc.
    • Covis Pharma
    • Tricida, Inc.
    • Eli Lilly and Company
    • Biosidus S.A.
    • Teva Pharmaceutical Industries Ltd.
    • YUHAN
    • Caladrius Biosciences, Inc.
    • UnicoCell Biomed CO. LTD
    • Akebia Therapeutics, Inc.
    • Allena Pharmaceuticals
    • KBP Biosciences Co., Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Route Of Administration
    • Market Snapshot, By Patient Type
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Regulatory Scenario
  • Key Highlights
  • Research and Development
  • Collaboration, Mergers, and Acquisitions Scenario
  • Key Development
  • Recent Product Approvals and Launches
  • PEST Analysis
  • Pipeline Analysis
  • Epidemiology

4. Global Chronic Kidney Disease Drugs Market- Impact of Coronavirus (Covid-19) Pandemic

  • COVID-19 Impact on the market
  • Impact on Global Chronic Kidney Disease Drugs Market
  • Impact on Clinical Trials

5. Global Chronic Kidney Disease Drugs Market, By Drug Class, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • ACE Inhibitors
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Angiotensin Receptor Blockers (ARBs)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • B-Blockers
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Calcium Channel Blockers
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Loop Diuretics
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Erythropoiesis-Stimulating Agents (ESAs)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Phosphate Binders
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Chronic Kidney Disease Drugs Market, By Route Of Administration, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Subcutaneous
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Intravenous
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Chronic Kidney Disease Drugs Market, By Patient Type, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Dialysis
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

9. Global Chronic Kidney Disease Drugs Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • AstraZeneca plc.
    • Amgen, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • AbbVie Inc.
    • ProKidney Corp.
    • Pfizer, Inc.
    • Bayer AG
    • F. Hoffmann-La Roche AG
    • Kissei Pharmaceutical Co., Ltd.
    • Reata Pharmaceuticals, Inc.
    • GlaxoSmithKline plc.
    • Ardelyx, Inc.
    • Boehringer Ingelheim International GmbH
    • Novo Nordisk A/S
    • Novartis AG
    • Johnson & Johnson
    • Astellas Pharma Inc.
    • Takeda Pharmaceutical Company Limited
    • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    • Kibow Biotech, Inc.
    • FibroGen, Inc.
    • Cara Therapeutics
    • Pieris Pharmaceuticals, Inc.
    • Mitsubishi Chemical Group Corporation
    • Pharmacosmos A/S
    • OPKO Health, Inc.
    • Covis Pharma
    • Tricida, Inc.
    • Eli Lilly and Company
    • Biosidus S.A.
    • Teva Pharmaceutical Industries Ltd.
    • YUHAN
    • Caladrius Biosciences, Inc.
    • UnicoCell Biomed CO. LTD.
    • Akebia Therapeutics, Inc.
    • Caladrius Biosciences, Inc.
    • Allena Pharmaceuticals
    • KBP Biosciences Co., Ltd.

11. Section

  • References
  • Research Methodology
  • About Us and Sales Contact